Growth Metrics

Vertex Pharmaceuticals (VRTX) Gross Profit (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 15 years of Gross Profit data on record, last reported at $2.6 billion in Q2 2025.

  • For Q2 2025, Gross Profit rose 12.47% year-over-year to $2.6 billion; the TTM value through Jun 2025 reached $9.7 billion, up 8.53%, while the annual FY2025 figure was $10.4 billion, 9.07% up from the prior year.
  • Gross Profit reached $2.6 billion in Q2 2025 per VRTX's latest filing, up from $2.5 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $2.6 billion in Q2 2025 and bottomed at $1.5 billion in Q1 2021.
  • Average Gross Profit over 5 years is $2.1 billion, with a median of $2.1 billion recorded in 2023.
  • Peak YoY movement for Gross Profit: rose 29.26% in 2021, then increased 4.08% in 2024.
  • A 5-year view of Gross Profit shows it stood at $1.8 billion in 2021, then rose by 10.64% to $2.0 billion in 2022, then grew by 6.45% to $2.1 billion in 2023, then grew by 15.76% to $2.5 billion in 2024, then grew by 2.76% to $2.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $2.6 billion in Q2 2025, $2.5 billion in Q4 2024, and $2.4 billion in Q3 2024.